Flumethasone pivalate
As of the edition of 20 October 2026, Flumethasone pivalate is a small molecule: marketed, first approved in 1968 (CA); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Locorten
- First approved
- 31 December 1968 (CA)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Novartis; 2 holders in all
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Flumethasone pivalate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Knight Therapeutics | Applicant | 1968 to now |
| Novartis | Applicant |